Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Tryckregulator - Serie 10

. Serie 10 kan monteras i panel, direkt på rörledning eller konsol.

Cleveland Clinic: Kirurgi gav fler långsiktiga fördelar än GLP-1-läkemedel

Metabol kirurgi minskade riskerna för död, hjärtsjukdom, njursvikt och ögonskador mer än GLP-1-läkemedel under en tioårsperiod. Det enligt en ny studie från Cle...

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...

Venomaid's rapid test aims to find the right snake bite treatment

Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom ca...

APV DW+ för känsliga produkter

SPX FLOW har introducerat APV DW+ förträngningspump, den senaste generationen av DW-serien.

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

Advance: Optimering med mätbart värde från dag ett

Ett flexibelt och holistiskt tillvägagångssätt för optimering av ånganläggningar.

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Svenske Martin Kulldorff bland nya vaccinrådgivare – utnämnd av Kennedy

USA:s hälsominister Robert Kennedy Jr. utsåg på onsdagen åtta nya ledamöter till CDC:s rådgivande vaccinkommitté (ACIP), efter att plötsligt ha avskedat hela de...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Bakslag för Pfizers prostataläkemedel

Läkemedelsjätten Pfizers försök att bredda användningsområdet för ett av sina läkemedel möter motstånd. En rådgivande panel hos läkemedelsmyndigheten FDA har en...

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

Accelerate your Research with AI-Powered Image Analysis

Comprehensive eBook from ZEISS.

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.